Published in AIDS Weekly, April 3rd, 2006
The price of the 600 mg formulation of Stocrin has been reduced by 20% to US$0.76 per day, or US$277.40 per patient per year, from $0.95 per day. The 200 mg formulation of Stocrin has been reduced by 22% to US$0.36 per capsule, or $1.08 per day and about US$394.20 per patient per year, from $0.46 per capsule. Merck is lowering the price of these formulations of Stocrin due to new efficiencies and cost savings resulting from improved manufacturing processes.
At the end of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.